These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 35771261)

  • 1. Clinical outcomes of PD-1/PD-L1 inhibitors in patients with advanced hepatocellular carcinoma: a systematic review and meta-analysis.
    Wen W; Zhang Y; Zhang H; Chen Y
    J Cancer Res Clin Oncol; 2023 Mar; 149(3):969-978. PubMed ID: 35771261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis.
    Rao Q; Li M; Xu W; Pang K; Guo X; Wang D; Liu J; Guo W; Zhang Z
    Hepatol Int; 2020 Sep; 14(5):765-775. PubMed ID: 32572818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.
    Zheng J; Shao M; Yang W; Ren J; Chen X; Yang H
    Int Immunopharmacol; 2022 Nov; 112():109244. PubMed ID: 36126410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual immune checkpoint inhibitors or combined with anti-VEGF agents in advanced, unresectable hepatocellular carcinoma.
    Zhang B; Tao B; Li Y; Yi C; Lin Z; Ma Y; Han J; Shao W; Chen Z; Lin J; Chen J
    Eur J Intern Med; 2023 May; 111():37-46. PubMed ID: 36588054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of PD-1/PD-L1 Inhibitors in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.
    Liu Y; Pan J; Gao F; Xu W; Li H; Qi X
    Adv Ther; 2023 Feb; 40(2):521-549. PubMed ID: 36399316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of PD-1/PD-L1 inhibitors combined with anti-angiogenic therapy for the unresectable hepatocellular carcinoma and the benefit for hepatitis B virus etiology subgroup: a systematic review and meta-analysis of randomized controlled trials.
    Huang D; Ke L; Cui H; Li S
    BMC Cancer; 2023 May; 23(1):474. PubMed ID: 37226111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the effectiveness and safety of combining PD-1/PD-L1 inhibitors with anti-angiogenic agents in unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
    Zhu H; Zhao W; Chen H; Zhu X; You J; Jin C
    Front Immunol; 2024; 15():1468440. PubMed ID: 39355241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The predictive value of PD-L1 expression in patients with advanced hepatocellular carcinoma treated with PD-1/PD-L1 inhibitors: A systematic review and meta-analysis.
    Yang Y; Chen D; Zhao B; Ren L; Huang R; Feng B; Chen H
    Cancer Med; 2023 Apr; 12(8):9282-9292. PubMed ID: 36965092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival Outcomes and Safety of Programmed Cell Death/Programmed Cell Death Ligand 1 Inhibitors for Unresectable Hepatocellular Carcinoma: Result From Phase III Trials.
    Zeng L; Su J; Qiu W; Jin X; Qiu Y; Yu W
    Cancer Control; 2022; 29():10732748221092924. PubMed ID: 35418272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical efficacy of lenvatinib, trans-arterial chemoembolization, and PD-1/L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and network meta-analysis.
    Liang Y; Gan L; Zeng D; Lin L; Xiong Z; Liao F; Wang A
    Clin Transl Oncol; 2024 Oct; 26(10):2652-2664. PubMed ID: 38671328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The benefit and risk of PD-1/PD-L1 inhibitors plus anti-angiogenic agents as second or later-line treatment for patients with advanced non-small-cell lung cancer: a systematic review and single-arm meta-analysis of prospective clinical trials.
    Chen S; Mo W; Jiang W; Zhou S; Gan H; Yu Q
    Front Immunol; 2023; 14():1218258. PubMed ID: 37614237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinico-characteristics of patients which correlated with preferable treatment outcomes in immunotherapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis.
    Wang Y; Lau W; Li Y; Tian Y; Lei Y; Wang J; Xia F
    Int J Surg; 2023 Nov; 109(11):3590-3601. PubMed ID: 37598406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
    Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
    Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
    [No Abstract]   [Full Text] [Related]  

  • 14. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
    Geng Y; Zhang Q; Feng S; Li C; Wang L; Zhao X; Yang Z; Li Z; Luo H; Liu R; Lu B; Wang X
    Cancer Med; 2021 Feb; 10(4):1222-1239. PubMed ID: 33465302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-1 inhibitors monotherapy in hepatocellular carcinoma: Meta-analysis and systematic review.
    Voutsadakis IA
    Hepatobiliary Pancreat Dis Int; 2019 Dec; 18(6):505-510. PubMed ID: 31551142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis.
    Mori K; Pradere B; Quhal F; Katayama S; Mostafaei H; Laukhtina E; Schuettfort VM; D'Andrea D; Egawa S; Bensalah K; Schmidinger M; Powles T; Shariat SF
    Cancer Treat Rev; 2021 Sep; 99():102242. PubMed ID: 34153830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Ba H; Liu L; Peng Q; Chen J; Zhu YD
    BMC Cancer; 2021 Nov; 21(1):1220. PubMed ID: 34774004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An investigative meta-analysis on the effectiveness and safety of integrating VEGF/VEGFR inhibitors with PD-1/PD-L1 inhibitors in cases with R/M HNSCC.
    Wang H; Hu L; Zhang F; Fang M; Xu J; Li M; Chen Z
    Oral Oncol; 2024 Jun; 153():106814. PubMed ID: 38714115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of PD-1/PD-L1 plus CTLA-4 antibodies ± other therapies in lung cancer: a systematic review and meta-analysis.
    Shen X; Huang S; Xiao H; Zeng S; Liu J; Ran Z; Xiong B
    Eur J Hosp Pharm; 2023 Jan; 30(1):3-8. PubMed ID: 34497128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.